Drugs /

nkx101

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) encoding for human natural-killer group 2, member D receptor protein (NKG2D; KLRK1; natural killer cell activating receptor group 2D) that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion of the allogeneic NKG2D-OX40-CD3zeta-CAR-mbIL-15-expressing NKs NKX101, these cells specifically target and bind to tumor cells expressing NKG2D ligands (NKG2DL). This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2DL-expressing tumor cells. In addition, these cells target, bind to and kill NKG2DL-expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. NKG2D ligands are overexpressed in a variety of cancer cells.

Clinical Trials

View Clinical Trials for nkx101

Nkx101 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating nkx101, 1 is phase 1 (1 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for nkx101 clinical trials.

Myelodysplastic syndromes is the most common disease being investigated in nkx101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Nkx101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating nkx101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
il-15-armored nkg2d ligands-targeting nkx101, allogeneic mbil-15/nkg2d-ox40-cd3zeta-car expressing nks nkx101, allogeneic nkg2d-ox40-cd3zeta-car-mbil-15-expressing natural killer cells
NCIT ID [1]:
C176027

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.